|
|
Post by boytroy88 on Jan 7, 2016 0:44:42 GMT -5
Spiro is uncertain about what will happen this year with MNKD. Because of the large amount of Afrezza inventory on hand, MNKD will most likely stop or slow production to a trickle, while furloughing most of the production and research staff to significantly reduce costs. MNKD will most likely reduce the wholesale costs of Afrezza by 40% or more to secure additional insurance coverage. . Spiro believes that MNKD will outsource it's Afrezza reps to a 2nd party Pharma, offering them 20 -25% commissions on sales. MNKD should within 2 to 3 months establish a small sales force of 15-20 people to target a particular state. Spiro believes that it is critical for MNKD to show steady Afrezza sales progress by late summer. If MNKD is successful in increasing sales significantly, Spiro believes that most of us will be able to start sleeping better by September 1, except for the people who sold all their shares today and yesterday. Spiro here, it looks like the Fat Lady was on the stage and had a mike in her hand, but Joeypotsandpans has sealed her mouth with duct tape and tied her hands behind her back. Her next slim chance to sing on this stage will not be for at least 12 month's. That's plan C. DeSisto will talk about plan A, B next Wed. So what's plan A and B? |
|
|
|
Post by kc on Jan 7, 2016 1:32:52 GMT -5
Spiro is uncertain about what will happen this year with MNKD. Because of the large amount of Afrezza inventory on hand, MNKD will most likely stop or slow production to a trickle, while furloughing most of the production and research staff to significantly reduce costs. MNKD will most likely reduce the wholesale costs of Afrezza by 40% or more to secure additional insurance coverage. . Spiro believes that MNKD will outsource it's Afrezza reps to a 2nd party Pharma, offering them 20 -25% commissions on sales. MNKD should within 2 to 3 months establish a small sales force of 15-20 people to target a particular state. Spiro believes that it is critical for MNKD to show steady Afrezza sales progress by late summer. If MNKD is successful in increasing sales significantly, Spiro believes that most of us will be able to start sleeping better by September 1, except for the people who sold all their shares today and yesterday. Spiro here, it looks like the Fat Lady was on the stage and had a mike in her hand, but Joeypotsandpans has sealed her mouth with duct tape and tied her hands behind her back. Her next slim chance to sing on this stage will not be for at least 12 month's. Your hired. I will pay you in Mallomars. |
|
|
|
Post by babaoriley on Jan 7, 2016 1:39:53 GMT -5
Who cares about proving something to SNY? They always intended to kill MNKD and the sooner we act with that realization, the better. Undercutting and destroying their prandial insulin products and profiting from doing so would be a really nice "in-your-face" and an appropriate response for the hose-job SNY gave MNKD. Yes, SNY wanted to kill MNKD so badly, they paid, what a couple of hundred million for the privilege?  |
|
|
|
Post by lakers on Jan 7, 2016 3:12:01 GMT -5
www.ibtimes.com.au/amid-weakening-diabetes-business-sanofi-cuts-ties-developer-inhaled-insulin-1498084Amid weakening diabetes business, Sanofi cuts ties with developer of inhaled insulin Sanofi Despite inhaled insulin being a less painful option for diabetics compared to injected insulin, pharmaceutical giant Sanofi, which markets the medication, reported sales of only €5 million (AUD$7.6 million) for the first three quarters of 2015. This disappointing sales figure led Sanofi to cut ties with MannKind, the developer of Afrezza. As it is Sanofi was also dealing with weak business from its diabetes drugs as the company projects annual decline of its business on the chronic ailment to 8 percent contraction in 2018 from 4 percent in 2015. This is due to price and product competition. Sanofi is the manufacturer of Lantus, a basal insulin injected once a day. The weak consumer response to Afrezza is on account of the inhalable being more expensive than Lantus, causing insurers to be reluctant to pay for the drug. The cost factor is on top of questions over allowing insulin to enter the lungs of a diabetic since the prescribing information recommends testing of lung function before use and periodical testing as well, reports The New York Times. According to Fiercepharma, Afrezza costs diabetics $7.54 (AUD$10.65) a day based on daily doses of 12 units, while Apidra – its injectable counterpart in Sanofi’s portfolio – costs only $3.14 (AUD$4.43) per day. Pharmacy checker gives a price range of $114.94 to $283 (AUD$162.33-$399.68) for 100 ml of Lantus. Even if injectable insulin is a less expensive option to Afrezza, diabetics, nevertheless are complaining of insulin price shock as its cost has soared over the years. Philly.com reports that the price of Lantus and Humalog, another prominent insulin brand, spiked 22.7 percent and 19.9 percent, respectively, from 2014 to 2015. Mark Schutta, endocrinologist at Penn Medicine, blames the spiraling price of insulin to corporate greed, while Barbara Simon, endocrinologist at Drexel, says that while there are multiple reasons for the price hike, the ones who are ultimately devastated are diabetics whom the insulin are supposed to help live longer. Nevertheless, despite the corporate divorce, the former business partners assured users of Afrezza of a smooth transition as Sanofi said it would continue with filling orders for the inhalable insulin until July 4. The inhalable insulin appears headed for the same fate as a similar medication manufactured by Pfizer which stopped making the alternative form of insulin due to weak sales also. If business was weak for Sanofi, it was worse for MannKind which reported a net loss of $91.4 million (AUD$129 million) in the first three quarters of 2015 even if it was Sanofi that shouldered the bulk of marketing expenses. The net loss worsens the financial standing of MannKind which has so far accumulated a deficit of $2.6 billion (AUD$3.67 billion) and $185 million (AUD$261.32 million) debt, although according to MannKind Chief Financial Officer Matthew Pfeffer, the firm has $60 million (AUD$84.75 million) cash enough to last it until the end of June 2016. However, at the rate injectable prices are rising, many diabetics are worried if their personal funds are enough to last them until mid-2016.
|
|
|
|
Post by peppy on Jan 7, 2016 5:55:46 GMT -5
Numbers so far on this thread;
 $186 / 30 = 6.2 a day.
Added: From the conference call
"It became clear as 2015 progressed, and sales forecasts were not met that change would be required for Afrezza to achieve market success that we believe and still believe is possible. We next began a process of independent research that helped us validate that new sales efforts and a different pricing strategy was required. "
Matt told us the plan.
"- education: physician, patients."
"redefining pricing, and contracting tactics to improve reimbursement and patient access to commercial and government payers."
"clean slate, new approach"
"Now non exclusive"
added : MNKD will most likely reduce the wholesale costs of Afrezza by 40% or more to secure additional insurance coverage. . Spiro believes that MNKD will outsource it's Afrezza reps to a 2nd party Pharma, offering them 20 -25% commissions on sales. MNKD should within 2 to 3 months establish a small sales force of 15-20 people to target a particular state. Spiro believes that it is critical for MNKD to show steady Afrezza sales progress by late summer.
|
|
|
|
Post by spiro on Jan 7, 2016 8:40:18 GMT -5
Peppy,
Don't believe a word of what that crazy guy Spiro says. He even told me last night, that MNKD has been awarded 7 of the Darkest Hour scenarios and that they have only used 4 of them so far. Most companies only get one of those Darkest Hour things.
John here, I can't believe that I listened to that Afrezza using Spiro for stock buying advice.
|
|
|
|
Post by peppy on Jan 7, 2016 8:52:15 GMT -5
I didn't use you for stock buying advice. I made all my own decisions.
I am caught by price, so at this point I need Afrezza and Mannkind to succeed.
I would like to see them pull it off mostly because I think it is a fine drug.
Type 1's have no choice they need a fast acting.
Tpye 2 I suppose the same, at some point.
To your health Spiro,
You take darn good pics.
|
|
|
|
Post by esstan2001 on Jan 7, 2016 8:56:05 GMT -5
Who cares about proving something to SNY? They always intended to kill MNKD and the sooner we act with that realization, the better. Undercutting and destroying their prandial insulin products and profiting from doing so would be a really nice "in-your-face" and an appropriate response for the hose-job SNY gave MNKD. Yes, SNY wanted to kill MNKD so badly, they paid, what a couple of hundred million for the privilege? The hit was agreed upon and sanctioned by the Cabal. They all have something to loose from Afrezza's success. (Shhh..don't tell anyone) |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 7, 2016 10:23:15 GMT -5
Spiro I am curious if you spoke with any early adopters that flew out to San Diego. Obviously I know they signed an NDA but are they baffled on why SNY flew them out there? Maybe I have it wrong did SNY even fly them out there? executive decisions dont match and dictate with day to day operations of how the team works/plans - until the day of axing - principle applies to any corporation I work for myself at home not in corp atmosphere so this doesnt even cross my mind. It totally makes sense. |
|
|
|
Post by robsacher on Jan 8, 2016 22:02:22 GMT -5
Spiro is uncertain about what will happen this year with MNKD. Because of the large amount of Afrezza inventory on hand, MNKD will most likely stop or slow production to a trickle, while furloughing most of the production and research staff to significantly reduce costs. MNKD will most likely reduce the wholesale costs of Afrezza by 40% or more to secure additional insurance coverage. . Spiro believes that MNKD will outsource it's Afrezza reps to a 2nd party Pharma, offering them 20 -25% commissions on sales. MNKD should within 2 to 3 months establish a small sales force of 15-20 people to target a particular state. Spiro believes that it is critical for MNKD to show steady Afrezza sales progress by late summer. If MNKD is successful in increasing sales significantly, Spiro believes that most of us will be able to start sleeping better by September 1, except for the people who sold all their shares today and yesterday. Spiro here, it looks like the Fat Lady was on the stage and had a mike in her hand, but Joeypotsandpans has sealed her mouth with duct tape and tied her hands behind her back. Her next slim chance to sing on this stage will not be for at least 12 month's. Awoke today with a positive perspective. We have our own fate now in our own hands. Afrezza is still the best insulin. |
|
